Commentary

NK1.1 + T Cell Receptor-α/β+ Cells: New Clues to Their Origin, Specificity, and Function

By H. Robson MacDonald

Although NK cells and T cells share a number of biological functions including cytotoxicity and lymphokine secretion (1), they appear to differ fundamentally in the structure of their antigen receptors. Whereas T cells are known to recognize foreign antigens via their CD3-associated heterodimeric α/β or γ/δ TCR, the antigen recognition structures used by NK cells are still in the process of being elucidated. In this respect, current evidence (2-5) suggests that NK cells express polymorphic (but nonrearranging) receptors that belong to the NKR-P1 and Ly-49 families in mouse and the recently cloned p58 family in humans. The nature of the ligands recognized by NK cells is controversial, although there is functional evidence that both Ly-49 and p58 receptor families may mediate negative signals upon engagement of particular MHC class I alleles (2-5). In contrast, NKR-P1 receptors appear to bind to a heterogeneous group of carbohydrate ligands (6), thereby triggering effector functions such as cytolysis (6, 7).

NK and T cells probably arise from related but distinct developmental lineages (8). Whereas the majority of α/β or γ/δ T cells depend upon the thymus for their development, NK cells develop normally in athymic (nude) mice. Furthermore, recombination-deficient mutant (RAG-/- or SCID) mice have normal levels of NK cells despite the complete absence of αβ or γδ T cells. Nevertheless, it is likely that both NK and T cells arise from a common "lymphoid committed" precursor cell, since both lineages (as well as B cells) are absent in mice lacking the ikaros transcription factor, whereas other hematopoietic cells develop normally in these mutant mice (9).

In view of the apparently distinct ligands recognized by NK cells and T cells, it is of considerable interest that a subset of lymphocytes sharing receptor structures common to both lineages has been identified in mice (10-12), rats (13), and humans (14, 15). In the mouse, the best-defined such population coexpresses the α/β TCR and NK1.1 (16) (a member of the NKR-P1 family), although other subsets of mouse TCR-α/β cells expressing members of the Ly-49 family have been described (17, 18). This commentary will focus on NK1.1+ TCR-α/β+ (hereafter referred to as NK1 + T) cells and, in particular, will summarize recent insights into their origin, specificity, and function.

Phenotype and TCR Expression of NK1.1+ T Cells

The surface phenotype of NK1 + T cells is dramatically different from that of normal αβ T cells. As summarized in Table 1, NK1 + T cells express a number of markers usually associated with an activation/memory phenotype (but absent from naive T cells) such as CD44high, CD45RBlow, and CD62Llow. In addition, NK1 + T cells express the IL-2Rβ chain (CD122), which is normally present on conventional NK cells but not T cells. Whereas most mature αβ T cells express either CD4 or CD8 coreceptors, NK1 + T cells are almost exclusively either CD4+ or CD4-8-. Another unique feature of NK1 + T cells relates to their TCR expression. In comparison with normal αβ T cells, NK1 + T cells express approximately threefold lower surface density of TCR-α/β and have often been referred to in the literature as TCR "intermediate" (TCRint) cells. Furthermore, the TCR usage of NK1 + T cells is heavily biased for both α and β chains. Thus, most NK1 + T cells use one of only three Vβ domains (Vβ8.2, Vβ7, or Vβ2) (19), and a single Vα domain (Vα14) is highly overrepresented among NK1 + T cells but rarely used by conventional αβ T cells (20). The latter finding explains the earlier puzzling observations of Taniguchi and co-workers (21), who identified a subset of peripheral T cells expressing an invariant Vα14-Jα281 rearrangement with no junctional diversity.

Relationship of NK1 + T Cells to TCRint, Invariant Vα14, and lpr/gld T Cells

An important (but not yet totally resolved) issue is the relationship of NK1 + T cells to other unusual TCR-α/β subsets. As noted above, both TCRint and invariant Vα14 T cell subsets have been described. Although all NK1 + T cells are clearly of a TCRint phenotype, it has not been possible technically to address whether other (NK1.1-) subsets of TCRint cells exist. In this issue of the journal, Sato et al. (22) provide a partial solution to this problem. By taking advantage of the expression of IL-2Rβ on all TCRint (but not conventional TCRhigh) cells, these authors show that NK1.1 defines only a subset of the TCRint population. Further analysis of CD4/8 phenotype indicates that most NK1.1+ TCRint cells are CD4+ or CD8-, whereas NK1.1- TCRint cells are mainly CD8+. It should be noted that the CD8+ TCRint subset, while resembling NK1 + T cells in terms of surface phenotype, has not yet been defined in terms of TCR usage or function.

The precise relationship between NK1 + T cells and invariant Vα14 cells has been more difficult to ascertain because of the absence of reliable antibodies against Vα14. Using semiquantitative PCR, Lantz and Bendelac (20) recently demonstrated a marked enrichment of Vα14+ cells in CD44high CD4+ thymocytes (corresponding to the CD4+..
Table 1. Phenotype and TCR Repertoire of NK1⁺ T Cells, Conventional T Cells, and lpr/gld T Cells

| Marker                  | NK1⁺ T | Naive T | Memory T | lpr/gld T |
|-------------------------|--------|---------|----------|-----------|
| NK1.1                   | +      | –       | –        | –         |
| CD4/8                   | CD4⁺ or| CD4⁺ or | CD4⁺ or  | CD4⁺/8⁻   |
| CD4⁺/8⁻                 | CD8⁺   | CD8⁺    |          |           |
| B220                    | –      | –       | –        | +         |
| CD44 (Pgp-1)            | High   | Low     | High     | High      |
| CD45RB                  | Low    | High    | Low      | High      |
| CD62L (Mel 14)          | Low    | High    | Low      | +/⁻       |
| CD24 (HSA)              | Low    | Low     | Low      | +/⁻       |
| CD122 (IL-2-Rβ)         | High   | Low     | Low      | Low       |
| TCR-CD3                 | Intermediate | High | High     | Intermediate |
| TCR Vβ                  | 2, 7, 8.2 | All  | All      | All       |
| TCR Vα                  | 14     | All     | All      | All       |
| Clonal deletion         | No     | Yes     | Yes      | Yes       |

Subset of thymic NK1⁺ T cells, and most T cell hybrids derived by fusion of this population to the BW5147 thymoma used the invariant Vα14-Jα281 rearrangement. Thus, it appears likely that most NK1⁺ T cells (but few conventional T cells) use Vα14; however, it is not known whether other TCR int subsets (such as the CD8⁺ TCR int population described above) are likewise enriched in Vα14⁺ cells.

Mice homozygous for the lpr or gld mutations (which are defective in functional Fas or Fas ligand, respectively) develop autoimmune syndromes accompanied by peripheral expansion of a unique subset of CD4⁻8⁻ TCR-α/β cells (23). These lpr/gld T cells resemble NK1⁺ T cells in that they are TCR int and express certain activation markers such as CD44hi; however, they differ phenotypically from NK1⁺ T cells in that they express the B cell marker B220 and fail to express NK1.1 (Table 1). Furthermore, lpr/gld T cells and NK1⁺ T cells differ fundamentally in their TCR repertoires (Table 1). Whereas NK1⁺ T cells use a highly restricted subset of Vβ and Vα chains, lpr/gld T cells have a much more diverse repertoire (although Vβ8 is somewhat overrepresented). Moreover, lpr and gld T cells are subject to deletional tolerance in the presence of endogenous mouse mammary tumor virus superantigens, whereas NK1⁺ T cells in general are not. Hence, it appears that lpr/gld T cells are not related to the NK1⁺ T lineage.

Developmental Origin of NK1⁺ T Cells

The developmental origin of NK1⁺ T cells is controversial. Historically, a T cell subset corresponding phenotypically to NK1⁺ T cells was first identified among CD4⁻8⁻ thymocytes (24, 25), although it was not appreciated for some time that these cells actually express NK1.1 (11). Subsequently, NK1⁺ T cells were observed in other lymphoid organs such as spleen (10) and bone marrow (12) as well as in liver (26). NK1⁺ T cells resident in the thymus appear to develop in situ, since cells of the NK1⁺ TCR-α/β⁺ phenotype can be generated in fetal thymus organ cultures established from 14-d mouse embryos (27). Furthermore, neonatal thymus grafts implanted in congenitally athymic (nude) mice can give rise to small numbers of NK1⁺ T cells in recipient bone marrow and spleen (28), suggesting a thymus-dependent origin for at least some peripheral NK1⁺ T cells. Nevertheless, NK1.1⁺ TCR-α/β⁺ cells are readily detectable in extrathymic tissues such as bone marrow (12), spleen (29), and liver (30) of nude mice. Thus, it appears that NK1⁺ T cells can be of either thymus-dependent or -independent origin. This conclusion is compatible with the finding that NK1⁺ T cells require expression of an endogenous ligand on hematopoietic cells (but not specialized epithelial cells) for their development (26, 27, 31).

New evidence for the extrathymic origin of at least some NK1⁺ T cells is presented by Sato et al. in this issue (22). In particular, these authors show that NK1⁺ T cells (and other TCR int cells) develop selectively in the liver and spleen of thymectomized irradiated F1 mice reconstituted with parental or syngeneic bone marrow cells. In control (euthymic) irradiated mice, both NK1⁺ T and conventional (TCR hiSh) T cells develop in these organs; however, the development of normal T cells is delayed relative to NK1⁺ T cells. The bone marrow precursors of NK1⁺ T cells in this adoptive transfer system express Thy-1 but not the TCR-CD3 complex. The findings of Sato et al. (22) are reminiscent of earlier reports in which TCR-α/β⁺ cells were shown to be generated in vitro from bone marrow precursors (32–34); however, a very recent study indicates that most TCR-α/β⁺
cells produced in short-term bone marrow cultures from Thy-1+ TCR-α/β− precursors are in fact NK1.1− (35).

If NK1+ T cells do indeed arise extrathymically, it should in theory be possible to demonstrate activity of the recombinease-activating genes (RAGs) (which are essential for TCR rearrangement) in NK1+ T precursor cells in the corresponding tissues. In this regard, RAG-1 and RAG-2 messenger RNA have been detected previously by PCR in liver mononuclear cells (36); however, no RAG-1 transcripts could be detected in liver by Northern blot in a subsequent study (37). Interestingly, Sato et al. (22) find that RAG-1 transcripts are expressed at much higher levels among liver mononuclear cells of reconstituted radiation bone marrow chimeras than in normal mouse liver. These data are consistent with an increased rate of extrathymic TCR-α/β rearrangement in NK1+ T cell precursors in the chimeric animals.

Ligand Specificity of NK1+ T Cells

As mentioned above, most NK1+ T cells express a TCR with a limited β chain (Vβ8.2, Vβ7, or Vβ2) and virtually invariant α chain (Vα14-Jα281) usage. It therefore seems likely that the ligand(s) for this TCR will be highly restricted (or even monomorphic). Several experiments in vivo using gene-targeted “knockout” mice have provided clues as to the potential ligands that control NK1+ T cell development. Thus, it is clear that NK1+ T cells in thymus (27, 31, 38) or liver (26), as well as the related Vα14+ peripheral T cell subset (39), fail to develop in β2-microglobulin (β2-m)−deficient mice, suggesting that a β2m-associated (i.e., MHC class I or related) molecule is a component of the ligand of the NK1+ T cell receptor. Further insight into the nature of this putative ligand comes from recent analysis of mice deficient for the peptide transporter-associated protein 1 (TAP-1). In these mice, which lack conventional MHC class I molecules (H-2K, D and L), Vα14+ T cells (and hence, presumably, most NK1+ T cells) develop normally (39). Taken together, the data with mutant mice suggest that NK1+ T cells recognize a β2m-associated molecule that does not require peptides transported by TAP-1 for its assembly and surface expression. Interestingly, there are at least two well-characterized molecules that fulfill these criteria: the thymus leukemia antigen (40) and CD1 (41). In this context, Taniguchi and co-workers have identified a wild mouse strain in which Vα14+ T cells do not develop. In F2 backcross analysis, this defect segregates as a single recessive gene that is unlinked to the MHC (39). If, indeed, the absence of Vα14+ cells in these wild mice reflects a defect in the ligand responsible for NK1+ T cell development, then it follows that the thymus leukemia antigen (which is closely linked to the MHC) cannot be the relevant ligand.

The case favoring CD1 as a potential ligand for NK1+ T cells has been greatly strengthened by very recent analysis of the specificity of NK1+ T hybridomas. Thus, Bendelac et al. (42) demonstrated that several hybridomas bearing the invariant Vα14-Jα281 rearrangement could be stimulated to produce lymphokines in vitro after exposure to CD1-expressing fibroblasts infected with a vaccinia construct containing the mouse CD1 gene. Furthermore, this stimulation could be inhibited by mAbs to either the TCR or to CD1. Weak reactivity of freshly isolated normal thymic NK1+ T cells to CD1-expressing fibroblasts could also be demonstrated. These data provide the first convincing evidence that CD1 is a component of the physiological ligand recognized by the TCR on NK1+ T cells. It will be of great interest to determine whether CD1 can associate with peptides or other nonpeptidic moieties to stimulate NK1+ T cells. In this respect, it is known that some human TCR-α/β+ clones can recognize mycolic acid (a mycobacterial cell wall product) in association with CD1b (43).

In considering the possible ligands recognized by NK1+ T cells, it should be emphasized that the potential contribution of the NK1.1 molecule itself to ligand specificity cannot be discounted. Indeed, NK1.1 is a member of the NKR-P1 family of C-type (calcium-dependent) lectins, and there is evidence that at least some members of this family may interact with complex oligosaccharides present on the surface of certain “NK-susceptible” target cells (6). In conventional NK cells, this interaction apparently leads to activation of the cytolytic program (6, 7). Furthermore, both NK cells (2) and activated NK1+ T cells (44) are capable of redirected lysis of Fc receptor-bearing target cells in the presence of anti-NK1.1 antibodies. Collectively, these data raise the possibility that the NK1.1 molecule on NK1+ T cells (or another NKR-P1 family member) may confer specificity for an oligosaccharide ligand and/or a carbohydrate component of a complex ligand (perhaps involving CD1) that is coregionized by the α/β TCR. In the latter case, NK1.1 could be considered as a type of coreceptor molecule that modifies the avidity of TCR–ligand interactions on NK1+ T cells. This speculative model (Fig. 1) is further supported by the fact that the cytoplasmic domains of NKR-P1 family members share a motif (Cys-X-Cys-Pro) that has been shown to be involved in the association of CD4 and CD8 coreceptors with the tyrosine kinase p56lck (2). However, no direct evidence for a molecular association between p56lck and NK1.1 has been reported.

Function of NK1+ T Cells

Because of the lack of precise knowledge of their ligand specificity, the function of NK1+ T cells under physiological conditions has been difficult to address. However, the functional potential of NK1+ T cells has been investigated in vivo and in vitro by triggering their TCR–CD3 complex with mAbs. Such studies have shown a remarkable ability of NK1+ T cells to produce large amounts of cytokines and, in particular, IL-4. Indeed, it is likely that virtually all the IL-4 produced in vitro by anti-CD3-stimulated thymocytes can be accounted for by the NK1.1+ T subset (45, 46), and similar conclusions have been reached for splenic T cells from normal mice injected with anti-CD3 mAbs (47). As pointed out by others (47), this property of NK1+ T cells may have important implications for the development of conventional CD4+ TCR-α/β+ cells of the Th2 cytokine profile, since, in many systems, Th2 cells arise preferentially (or exclusively)
DNP use the identical α chain (54). Although the actual mechanism of suppression mediated by such hybridomas is still not well defined, it is tempting to speculate that NK1+ T cells may in general be involved in negative regulatory functions, perhaps facilitated by their cytolytic activity and potential to secrete large amounts of inhibitory cytokines.

A more physiological regulatory function of NK1+ T cells relates to the suppression of hemopoiesis. It has been known for many years that irradiated F1 mice frequently reject parental bone marrow grafts. The phenomenon, known as hybrid resistance, is genetically complex and involves the participation of NK1.1+ effector cells (55). Whereas it was initially assumed that these effector cells are conventional NK cells, several studies clearly implicate NK1+ T cells in hybrid resistance (10, 56). This issue is currently controversial, and it is possible that both NK and NK1+ T cells may be involved in the suppression of hemopoiesis (55).

**Figure 1. Speculative coreceptor model for CD1 ligand recognition by NK1+ T cells.** In this model, the highly conserved TCR-α/β on NK1+ T cells reacts with the nonpolymorphic CD1 molecule. At the same time, the extracellular C-type lectin domain of NK1.1 interacts with a carbohydrate moiety on CD1 to stabilize TCR binding. By analogy with CD4 and CD8 on conventional T cells, NK1.1 could thus signal as a coreceptor via its putative cytoplasmic association with the tyrosine kinase p56lck. It is not known whether the peptide-binding groove of CD1 is occupied, and the putative carbohydrate moiety could be of either endogenous or exogenous origin. Note that NK1.1 is a homodimer and hence could theoretically cross-link TCR-CD1 complexes.

A more physiological regulatory function of NK1+ T cells is in the context of immune responses (10, 56). This issue is currently controversial, and it is possible that both NK and NK1+ T cells may be involved in the suppression of hemopoiesis (55).

**NK1+ T Cells Expressing TCR-γ/δ**

This commentary has focused on the well-established subset of NK1+ T cells that expresses TCR-α/β. However, in this issue of the journal, Arase et al. (57) describe a novel population of TCR-γ/δ+ NK1+ T cells that is present in very low frequency in normal thymus. Interestingly, TCR-γ/δ+ NK1+ T cells are increased dramatically in the thymus of CD3-γ-deficient mice, where, in contrast, mature TCR-α/β+ cells (including the NK1+ T subset) fail to develop. By analogy to conventional TCR-γ/δ+ cells present in the gut epithelium (58), it is likely that thymic TCR-γ/δ+ NK1+ T cells are able to develop in CD3-γ-deficient mice because the CD3-γ-chain in their TCR complex can be substituted by the homologous FceRI γ chain, which normally associates with CD16 to form the high affinity Fc receptor (59, 60). In any event, it will be of considerable interest to further characterize this novel NK1.1+ TCR-γ/δ+ subset in terms of its origin and function. Given the paucity of information concerning the physiological ligand recognized by conventional TCR-γ/δ cells, it will be particularly challenging to address the specificity of the NK1.1+ TCR-γ/δ receptor.

As a first approach, it will obviously be informative to investigate whether V gene usage is biased in these cells, as is the case for the TCR-α/β+ NK1+ T subset.

**Concluding Remarks**

NK1+ T cells represent a fascinating subset of TCR-α/β (and apparently TCR-γ/δ) cells with poorly defined ligand specificity. As outlined here, it appears likely that NK1+ T cells can develop independently in several extrathymic tissues (notably bone marrow and liver) as well as in the thymus. Because of their ability to secrete large amounts of IL-4 upon TCR engagement, NK1+ T cells may play a pivotal role in Th1/Th2 lineage commitment of conventional CD4+ TCR-α/β+ cells. Furthermore, the potential of NK1+ T cells to mediate target cell lysis under certain conditions may allow them to carry out other regulatory functions, such as the suppression of immune responses or of hemopoiesis. Ultimately, NK1+ T cells may turn out to be bona fide regulatory T cells that can even be discussed openly in public (61).
References

1. Trinchieri, G. 1989. Biology of natural killer cells. *Adv. Immunol.* 47:187-376.

2. Yokoyama, W.M., and W.E. Seaman. 1993. The Ly-49 and NKR-P1 gene families encoding lectin-like receptors on natural killer cells: the NK gene complex. *Annu. Rev. Immunol.* 11:613-635.

3. Moretta, L., E. Ciccone, M.C. Mignani, R. Biasioni, and A. Moretta. 1994. Human natural killer cells: origin, clonality, specificity and receptors. *Adv. Immunol.* 55:341-380.

4. Wagtmann, N., R. Biasioni, C. Cantoniti, S. Verfalli, M.S. Malnati, M. Vitale, C. Bothno, L. Moretta, A. Moretta, and E.O. Long. 1995. Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related molecules with diversity in both the extra- and intracellular domains. *Immunity.* 2:439-449.

5. Colonna, M., and J. Samaridis. 1995. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. *Science (Wash. DC).* 268:405-408.

6. Bezouska, K., C.T. Yuen, J. O'Brien, R.A. Childs, W. Chai, A.M. Lawson, K. Drbal, A. Fiserova, M. Pospisil, and T. Feizi. 1994. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. *Nature (Lond.)* 372:150-157.

7. Ryan, J.C., E.C. Niemi, M.C. Nakamura, and W.E. Seaman. 1995. NKR-P1A is a target-specific receptor that activates natural killer cell cytotoxicity. *J. Exp. Med.* 181:1911-1915.

8. Lanier, L.L., H. Spits, and J.H. Phillips. 1992. The developmental relationship between NK cells and T cells. *Immunol. Today.* 13:392-395.

9. Georgopoulos, N., M. Bigby, J.-H. Wang, A. Molnar, P. Wu, S. Winandy, and A. Sharpe. 1994. The il2rs gene is required for the development of all lymphoid lineages. *Cell.* 79:143-156.

10. Yankelevich, B., C. Knobloch, M. Nowicki, and G. Dennenr. 1989. A novel cell type responsible for narrow graft rejection in mice. T cells with NK phenotype cause acute rejection of narrow grafts. *J. Immunol.* 142:3423-3430.

11. Ballas, Z.K., and W. Rasmussen. 1990. Unusual T cell populations in adult bone marrow. Prevalence of CD3-CD8+CD4- and CD4-CD8- T cells. *J. Immunol.* 145:1039-1045.

12. Sykes, M. 1990. Unusual T cell populations in adult bone marrow. Prevalence of CD3-CD4-CD8- and αβTCR - NK1.1+ cells. *J. Immunol.* 145:3209-3215.

13. Bezouska, K., C.T. Yuen, J. O'Brien, R.A. Childs, W. Chai, A.M. Lawson, K. Drbal, A. Fiserova, M. Pospisil, and T. Feizi. 1994. Oligosaccharide ligands for NKR-P1 protein activate NK cells and cytotoxicity. *Nature (Lond.)* 372:150-157.

14. Lanier, L.L., H. Spits, and J.H. Phillips. 1992. The developmental relationship between NK cells and T cells. *Immunol. Today.* 13:392-395.

15. Trinchieri, G. 1989. Biology of natural killer cells. *Adv. Immunol.* 47:187-376.
mice. *J. Immunol.* **149:**403–412.

30. Hashimoto, W., K. Takada, R. Anzai, K. Ogasawara, H. Sakihara, K. Sugiyama, S. Seki, and K. Kumagai. 1995. Cytotoxic NK1.1 Ag+ αβ T cells with intermediate TCR induced in the liver of mice by IL-12. *J. Immunol.* **154:**4333–4340.

31. Bix, M., M. Coles, and D. Rautel. 1993. Positive selection of Vß8*CD4+8* thymocytes by class I molecules expressed by hematopoietic cells. *J. Exp. Med.* **178:**901–908.

32. Benveniste, P., R.S. Chadwick, R.G. Miller, and J. Reimann. 1990. Characterization of cells with T cell markers in thymic nude bone marrow and of their in vitro-derived clonal progeny. Comparison with euthymic bone marrow. *J. Immunol.* **144:**411–419.

33. Palathumpat, V., S. Debjakhsh-Jones, B. Holm, H. Wang, O. Liang, and S. Strober. 1992. Studies of CD4+CD8~αβ bone marrow T cells with suppressor activity. *J. Immunol.* **148:**373–380.

34. Kubota, H., H. Okazaki, M. Onuma, S. Kano, M. Hattori, H. Koseki, M. Kanno, and M. Taniguchi. 1993. Extrathymic T cells and expansion of NKI.1+ T cell develop-

35. Dejbakhsh-Jones, S., H. Okazaki, and S. Strober. 1995. Similar rates of production of T and B lymphocytes in the bone marrow. *J. Exp. Med.* **181:**2201–2211.

36. Makino, Y., N. Yamagata, T. Sasho, Y. Adachi, R. Kanno, H. Koseki, M. Kanno, and M. Taniguchi. 1993. Extrathymic development of Var14-positive T cells. *J. Exp. Med.* **167:**1399–1408.

37. Crispe, I.N., and L. Huang. 1994. Neonatal, moribund and undead T cells: the role of the liver in T cell development. *Seminars Immunol.* **6:**39–41.

38. Coles, M.C., and D. Rautel. 1994. Class I dependence of the development of CD4+CD8~αβ NK1.1+ thymocytes. *J. Exp. Med.* **180:**395–399.

39. Adachi, Y., H. Koseki, M. Zijlstra, and M. Taniguchi. 1995. Positive selection of invariant Var14+ T cells by non-major histocompatibility complex-encoded class I-like molecules expressed on bone marrow-derived cells. *Proc. Natl. Acad. Sci. USA.* **92:**1200–1204.

40. Holcombe, H.R., A.R. Cañada, H. Cheronet, M. Teitel, J.K. Mah ♥, P.A. Peterson, and M. Kronenberg. 1995. Non-classical behavior of the thymus leukemia antigen: peptide transporter-dependent expression of a nonclassical class I mole-

41. de la Salle, H., M. Hanau, D. Fricker, A. Urlacher, A. Kelly, J. Salamero, S.H. Powis, L. Donato, H. Basinger, M. Jeras, et al. 1994. Homozygous human TAP peptide transporter muta-

42. Bendelea, A., O. Lantz, M.E. Quimby, J.W. Yewdell, J.R. Ben-

43. Beckman, E.M., S.A. Porcelli, C.T. Morita, S.M. Behar, S.T. Furlong, and M.B. Brenner. 1994. Recognition of a lipid antigen by CD1-restricted αβ T cells. *Nature (Lond.)* **372:**691–694.

44. Takada, K., and G. Dennert. 1994. Demonstration of MHC class I-specific cytolytic activity in IL-2-activated NK1.1+CD3+ cells and evidence of usage of T and NK cell receptors. *Transplantation (Baltimore).* **58:**496–504.

45. Zlotnik, A., D.I. Godfrey, M. Fischer, and T. Suda. 1992. Cytokine production by mature and immature CD4+CD8~T cells, αβ-T cell receptor+ CD4+CD8~T cells produce IL-4. *J. Immunol.* **149:**1121–1125.

46. Arase, H., N. Arase, K. Nakagawa, R.A. Good, and K. Ono6. 1993. NK1.1+CD4+CD8~ thymocytes with specific lymphokine secretion. *Eur. J. Immunol.* **23:**307–310.

47. Yoshimoto, T., and W.E. Paul. 1994. CD4~, NK1.1+ T cells prompty produce interleukin 4 in response to in vivo challenge with anti-CD3. *J. Exp. Med.* **179:**1285–1295.

48. Gallo, K.J., and R.L. Coffman. 1994. A minority subpopula-

49. Ballas, Z.K., and W. Rasmussen. 1993. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8αβ+ B220~ lymphokine-activated killer subset. *J. Immunol.* **150:**17–30.

50. Koyasu, S. 1994. CD3~+CD16~NK1.1~B220~ large granular lymphocytes arise from both αβ-TCR+CD4~+ and γδ-TCR+CD4~+ cells. *J. Exp. Med.* **179:**1957–1972.

51. Arase, H., N. Arase, Y. Kobayashi, Y. Nishimura, S. Yone-

52. Bradbury, A., F. Calabi, and C. Milstein. 1990. Expression of CD1 in the mouse thymus. *Eur. J. Immunol.* **20:**1831–1836.

53. Koseki, H., K. Inai, T. Ichikawa, I. Hayata, and M. Taniguchi. 1989. Predominant use of a particular αβ-chain in suppressor T cell hybridomas specific for keyhole limpet hemocyanin. *Int. Immunol.* **1:**557–564.

54. Barbo, J.V., J.E. McCormack, J.W. Moorhead, and R.J. Fair-

55. Yu, Y.Y.L., V. Kumar, and M. Bennett. 1992. Murine natural killer cells and marrow graft rejection. *Annu. Rev. Immunol.* **10:**189–213.

56. Kikly, K., and G. Dennert. 1992. Evidence for a role of T cell receptors (TCR) in the effector phase of acute bone marrow graft rejection. *J. Immunol.* **149:**3489–3494.

57. Arase, H., S. Ono, N. Arase, S.Y. Park, K. Wakisaka, H. Watanabe, H. Ohno, J.V. Ravetch, and T. Saito. 1995. Devel-

58. Malissen, M., A. Gillet, B. Rocha, J. Trucy, E. Vivier, C. Boyer, M. Fahrig, N. Brun, G. Mazza, E. Spanopoulou, et al. 1993. T cell development in CD3~−/− mutant mice. *J. Exp. Med.* **182:**891–895.

59. Ohno, H., S. Ono, N. Hirayama, S. Shimada, and T. Saito. 1994. Preferential usage of the Fc receptor γ chain in the T cell antigen receptor complex by γδ T cells localized in epithelia. *J. Exp. Med.* **179:**365–369.

60. Liu, C.-P., R. Ueda, J. She, J. Sancho, B. Wang, G. Weddell, J. Loring, C. Kurahara, E.C. Dudley, A.C. Hayday, et al. 1993. Abnormal T cell development in CD3~−/− mutant mice and identification of a novel T cell population in the intestine. *EMBO (Eur. Mol. Biol. Organ.)* **J.** **12:**4863–4875.

61. Green, D.R., and D.R. Webb. 1993. Saying the "S" word in public. *Immunol. Today.* **14:**523–525.